#United States #New York #Gastroesophageal Cancer #DeGregorio Family Foundation #Timothy C. Wang

DeGregorio Family Foundation Grants $500K for Groundbreaking Cancer Therapy

In a remarkable step towards innovative cancer treatments, the DeGregorio Family Foundation, in collaboration with the Torrey Coast Foundation, has awarded a $250,000 grant to Dr. Timothy C. Wang of Columbia University. This funding is part of a larger $500,000 grant aimed at accelerating research into a novel therapy for gastroesophageal cancer, aligning with the foundation's commitment to fighting this formidable disease.

Dr. Wang, who serves as the Chief of the Division of Digestive and Liver Diseases at the Irving Cancer Research Center, is a prominent figure in cancer research, particularly in understanding the molecular mechanisms behind carcinogenesis. He expressed gratitude for the foundation's focus on gastroesophageal cancers and its support in developing innovative therapies.

Gastroesophageal cancer is alarmingly prevalent, being one of the leading causes of cancer-related deaths globally, with over 30,000 new cases diagnosed annually in the United States alone. Traditional treatments, such as chemotherapy and immunotherapy, have shown limited effectiveness, particularly due to the presence of immunosuppressive neutrophils that inhibit the action of T cells against tumors. Dr. Wang's research explores how a small peptide, known as TFF2, can modulate these neutrophils to create a more favorable environment for anti-tumor immune responses.

The studies conducted by Dr. Wang's team have demonstrated that TFF2 can selectively target and eliminate harmful neutrophils while preserving beneficial ones, leading to a substantial reduction in tumor size and improved survival rates in animal models. By conjugating TFF2 with albumin—a protein that enhances the stability and efficacy of the therapy—Dr. Wang aims to make this treatment more practical and adaptable, potentially allowing it to be administered less frequently and in combination with other therapeutic agents.

This research is critical, considering that in 2022 alone, gastroesophageal cancers claimed over 1.1 million lives worldwide. The complexity and resilience of these cancers pose significant challenges for effective treatment, as they often exhibit chemo-resistant behaviors and a proclivity for metastasis, leading to poor prognoses.

Lynn DeGregorio, President and Founder of the DeGregorio Family Foundation, emphasized the importance of Dr. Wang's work, suggesting that the ongoing research brings them closer to clinical trials and possibly groundbreaking treatment options for patients. The foundation itself has a poignant history, having been established after a family member lost their battle with stomach cancer, and has since raised more than $15 million to advance research efforts in this field.

Dr. Wang's innovative approach marks a significant progression in the quest for better treatments for gastroesophageal cancer, which remain both a medical challenge and a personal one for many families affected by this disease. For those looking to contribute to this vital cause, the DeGregorio Family Foundation welcomes donations to support continued research and development of effective therapies.

This initiative not only fosters hope for patients but also highlights the importance of private funding in elevating groundbreaking research that could lead to durable solutions in the fight against cancer. As research progresses, the potential for developing effective treatments for gastroesophageal cancer will only become more tangible, ultimately benefiting countless individuals affected by this devastating illness.